We are live on ! Find out more
GILD icon

Gilead Sciences

1,630 hedge funds and large institutions have $97.1B invested in Gilead Sciences in 2016 Q1 according to their latest regulatory filings, with 119 funds opening new positions, 738 increasing their positions, 656 reducing their positions, and 99 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more first-time investments, than exits

New positions opened: 119 | Existing positions closed: 99

13% more repeat investments, than reductions

Existing positions increased: 738 | Existing positions reduced: 656

0% more funds holding

Funds holding: 1,6281,630 (+2)

6% less call options, than puts

Call options by funds: $1.74B | Put options by funds: $1.84B

16% less capital invested

Capital invested by funds: $116B → $97.1B (-$19.2B)

17% less funds holding in top 10

Funds holding in top 10: 224187 (-37)

Holders
1,630
Holders Change
+2
Holders Change %
+0.12%
% of All Funds
43.42%
Holding in Top 10
187
Holding in Top 10 Change
-37
Holding in Top 10 Change %
-16.52%
% of All Funds
4.98%
New
119
Increased
738
Reduced
656
Closed
99
Calls
$1.74B
Puts
$1.84B
Net Calls
-$105M
Net Calls Change
+$506M
Name Holding Trade Value Shares
Change
Change in
Stake
CM
276
Castleark Management
Illinois
$30.9M -$3.26M -36,160 -10%
RG
277
Renaissance Group
Kentucky
$30.9M +$3.54M +39,264 +13%
EIM
278
ExxonMobil Investment Management
Texas
$30.6M +$881K +9,765 +3%
RSCM
279
Rock Springs Capital Management
Maryland
$30.3M +$451K +5,000 +2%
BC
280
Bartlett & Co
Ohio
$30.3M +$1.76M +19,495 +6%
FAF
281
Fjarde Ap-fonden
Sweden
$30.1M +$3.3M +36,544 +13%
Balyasny Asset Management
282
Balyasny Asset Management
Illinois
$30.1M +$29M +321,256 +5,192%
Handelsbanken Fonder
283
Handelsbanken Fonder
Sweden
$30.1M -$14.5M -160,703 -33%
Connor, Clark & Lunn Investment Management (CC&L)
284
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$30M -$11.5M -127,200 -28%
AAMU
285
AEGON Asset Management (UK)
United Kingdom
$30M -$1.13M -12,579 -4%
SAM
286
Sentinel Asset Management
Vermont
$29.9M +$45.1K +500 +0.2%
JIM
287
Jupiter Investment Management
United Kingdom
$29.8M -$54M -598,450 -65%
Fidelity International
288
Fidelity International
Bermuda
$29.6M -$6.39M -70,829 -18%
WBC
289
Westpac Banking Corp
Australia
$29.6M -$127M -1,407,324 -81%
WMC
290
Westwood Management Corporation
Illinois
$29.3M +$126K +1,400 +0.4%
HighTower Advisors
291
HighTower Advisors
Illinois
$29.3M -$3.25M -36,077 -10%
MME
292
Meag Munich Ergo
Germany
$29.1M +$8.08M +89,644 +40%
SW
293
SVB Wealth
Massachusetts
$29.1M +$884K +9,802 +3%
PWLP
294
Prio Wealth Limited Partnership
Massachusetts
$29M -$9.3M -103,117 -25%
Baird Financial Group
295
Baird Financial Group
Wisconsin
$28.9M +$8.75K +97 +0%
GG
296
Gofen & Glossberg
Illinois
$28.6M +$443K +4,912 +2%
Commonwealth Equity Services
297
Commonwealth Equity Services
Massachusetts
$28.4M +$3.93M +43,573 +16%
IC
298
Inverness Counsel
New York
$28.4M +$307K +3,407 +1%
PAI
299
Palo Alto Investors
California
$27.8M
SB
300
Suntrust Banks
Georgia
$27.3M -$10.9M -121,148 -29%

GILD Hedge Fund Activity: Q1 2016 in Review

1,630 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q1 2016, worth a combined $97.1B — down 16% from $116B a quarter earlier.

Buyers outnumbered sellers: 119 funds opened new GILD positions and 99 closed out — a net gain of 20 holders — while 738 added to existing stakes and 656 trimmed.

The largest buyer was Royal London Asset Management, adding an estimated $2.73B. The largest seller was Capital Research Global Investors, cutting an estimated $1.99B.

  • 1,630 institutional investors held Gilead Sciences (GILD) as of Q1 2016, up from 1,628 in Q4 2015.
  • Funds reported $97.1B of Gilead Sciences stock for Q1 2016, down 16% quarter-over-quarter.
  • 119 funds opened new Gilead Sciences positions in Q1 2016 and 99 closed out, a net change of +20 holders.
  • The largest Gilead Sciences buyer in Q1 2016 was Royal London Asset Management, an estimated $2.73B added.
  • The largest Gilead Sciences seller in Q1 2016 was Capital Research Global Investors, an estimated $1.99B sold.

Based on aggregated 13F filings for Q1 2016.